source
- Revolution Medicines' Rasonque generates $198 million in sales within five weeks of U.S. approvalRevolution Medicines reported that its pancreatic cancer therapy Rasonque has achieved $198 million in revenue in the first five weeks after receiving U.S. approval. The company said more than 5,00…
- Novartis reports nine tumor cases in patients treated with Zolgensma gene therapyNovartis has confirmed that nine cases of tumors have been reported in patients who received its spinal muscular atrophy gene therapy, Zolgensma. The company says two cases are confirmed and seven…